Trials / Terminated
TerminatedNCT01820078
Paricalcitol on Albuminuria, Inflammation and Fibrosis on Proteinuric Chronic Renal Diseases (PALIFE Study)
Effect of Paricalcitol on Albuminuria, Inflammation and Fibrosis on Proteinuric Chronic Renal Diseases (PALIFE Study): a Randomized Study
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 127 (actual)
- Sponsor
- Fundación Renal Iñigo Alvarez De Toledo · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to estimate the differences between albuminuria values determined as Urine Albumin-to-Creatinine Ratio (UACR)(log transformed) from baseline to last observation caused by paricalcitol between the group of control and group of treatment.
Detailed description
Clinical Trial to estimate UACR determined albuminuria differences between treatment and non-treatment groups from basal intake to last study-related observation. Patients should suffer proteinuric Chronical Kidney Disease and recovered levels of seric 25(OH)D. Also, this clinical trial tries to determinate the effect of paricalcitol over several metabolic and inflammatory parameters on patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Experimental arm | Oral paricalcitol, 1 ug/day, plus daily treatment. 6 months (all study) |
| OTHER | Comparator Arm | Daily treatment is not define by protocol, because daily treatment in CKD is highly variable and includes salt and/or blood pressure regulation, angiotensine system stoppers, controlled diet, etc. |
Timeline
- Start date
- 2012-05-01
- Primary completion
- 2013-09-01
- Completion
- 2013-12-01
- First posted
- 2013-03-28
- Last updated
- 2013-11-28
Locations
25 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT01820078. Inclusion in this directory is not an endorsement.